The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
A. Veccia
No relevant relationships to disclose
O. Caffo
No relevant relationships to disclose
S. Brugnara
No relevant relationships to disclose
A. Caldara
No relevant relationships to disclose
M. C. di Pasquale
No relevant relationships to disclose
A. Ferro
No relevant relationships to disclose
M. Frisinghelli
No relevant relationships to disclose
V. Murgia
No relevant relationships to disclose
B. Soini
No relevant relationships to disclose
F. Valduga
No relevant relationships to disclose
G. L. Pappagallo
No relevant relationships to disclose
E. Galligioni
No relevant relationships to disclose